Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders

Published:2023-07-12 Issue:14 Volume:7 Page:3431-3434
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Schieber Timothy¹^ORCID,Li Anthony¹,Lundberg Jordan¹,Wiczer Tracy¹,Voorhees Timothy²^ORCID

Affiliation:

1. 1Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH

2. 2Department of Medicine-Hematology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/14/3431/2065272/blooda_adv-2022-009548-main.pdf

Reference14 articles.

1. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience;Salles;Adv Ther,2017

2. Treatment with rituximab in Benign and malignant hematologic disorders in children;Giulino;J Pediatr,2007

3. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients;van Vollenhoven;Ann Rheum Dis,2013

4. Rituximab hypersensitivity: from clinical presentation to management;Fouda;Front Pharmacol,2020

5. A tale of two antibodies: obinutuzumab versus rituximab;Freeman;Br J Haematol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells;Frontiers in Immunology;2024-04-04

2. Obinutuzumab/rituximab;Reactions Weekly;2023-11-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3